PolyPeptide Group AG (PLYGF) upgrades 2026 guidance amid strong metabolic drug demand and a proposed acquisition by Samsung Biologics.

Completion of the deal is anticipated towards the end of 2026.

Swiss drugmaker reviews options after takeover interest reports, highlighting early-stage discussions with no assurance of outcome

Private equity circles a niche pharma player that’s quietly become more valuable than it looks.

KKR is facing a wave of investor redemption requests in its private credit funds, prompting withdrawal limits similar to those seen at other large asset managers. The redemption pressure highlights client concerns around liquidity in private markets and the structure of semi-liquid credit vehicles. At the same time, KKR is reported to be exploring an acquisition of PolyPeptide Group, a move that would extend its reach in pharmaceutical and biotech services. For investors watching NYSE:KKR,...

PolyPeptide Group AG (PLYGF) reports a 16% revenue increase and significant EBITDA margin improvement, while navigating challenges and setting ambitious growth targets for 2026.

Key Insights Using the 2 Stage Free Cash Flow to Equity, PolyPeptide Group fair value estimate is CHF30.75 PolyPeptide...

While PolyPeptide Group AG ( VTX:PPGN ) might not have the largest market cap around , it led the SWX gainers with a...